ADILW - Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office | Benzinga
CHARLOTTESVILLE, Va., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it has been awarded an important patent which expands the estate covering the combination of the Company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the Company's lead investigational new drug product AD04.
"Following a post hoc analysis of our ONWARD™ Phase 3 results, we identified patients with specific genotypes that responded extremely well to AD04. Given the positive results, we believe the combination of our genetic diagnostic and AD04 can provide a tailored treatment solution for those who suffer from AUD and OUD," commented Cary Claiborne, CEO of Adial Pharmaceuticals. "This key patent significantly expands the scope of our intellectual property (IP) protection in the United States to cover important aspects of our unique molecular approach to diagnosing and potentially treating AUD and other drug dependencies such as OUD. By combining a tool to predict which patients are most likely to benefit from AD04 treatment, with AD04's clinical track record of reducing heavy drinking days among patients with specific genotypes, we believe we can transform the lives of millions affected by AUD and other dependencies. Among patients with the target genotypes, we believe the addressable market for AD04 is approximately $40 billion, in the U.S. alone. We remain committed to further understanding the genetic factors that affect addiction and bringing a personalized approach ...